Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 6:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 296 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis B Virus (HBV) Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Planet Hepatitis B

NCT04503993
View directory record Official record
Conditions
Hepatitis B
Interventions
Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 75 Years
Enrollment
5,004 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth

NCT00106964
View directory record Official record
Conditions
HIV Infection, Hepatitis B
Interventions
Engerix-B 20 mcg, Engerix-B 40 mcg, Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients

NCT00051038
View directory record Official record
Conditions
Hepatitis B
Interventions
Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
5
States / cities
New Haven, Connecticut • Altamonte Springs, Florida • Lousiville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 11, 2026, 6:14 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy

NCT07658976
View directory record Official record
Conditions
HIV Infection, Sexually Transmitted Infection
Interventions
HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package, Handout about HIV PrEP options available at the site, Standard-of-care HIV PrEP counseling from qualified study staff
Drug · Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years to 29 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Los Angeles, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

NCT01548690
View directory record Official record
Conditions
Acute Liver Failure, Acute Liver Injury
Interventions
Ornithine Phenylacetate
Drug
Lead sponsor
William Lee
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

Simvastatin for the Treatment of Chronic Hepatitis B

NCT00994773
View directory record Official record
Conditions
Hepatitis B
Interventions
Simvastatin, Tenofovir, Entecavir
Drug
Lead sponsor
Bader, Ted, M.D.
Individual
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Oct 11, 2026, 6:14 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy

NCT04046107
View directory record Official record
Conditions
Hepatitis B Virus
Interventions
Cemiplimab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)

NCT04449029
View directory record Official record
Conditions
Hepatitis B
Interventions
GSK3228836, Placebo, Nucleos(t)ide therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 11, 2026, 6:14 PM EDT
Not listed Phase 2 Interventional

4-Methylumbelliferone as a Treatment for Chronic HBV/HCV

NCT00225537
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
4-Methylumbelliferone (Heparvit®)
Drug
Lead sponsor
MTmedical Institute of Health
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

NCT02296853
View directory record Official record
Conditions
Hepatitis B Virus
Interventions
TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Results available

A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

NCT00962871
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
peginterferon alfa-2a [Pegasys], tenofovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People

NCT00100633
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
CpG7909 oligodeoxynucleotides (ODN), Hepatitis B virus vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2008 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 2 Interventional

Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

NCT00013702
View directory record Official record
Conditions
Hepatitis B, HIV Infection
Interventions
Adefovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 11, 2026, 6:14 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus

NCT00496002
View directory record Official record
Conditions
Chronic Hepatitis, Hepatitis B
Interventions
Clevudine, Adefovir
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Anaheim, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2009 · Synced Oct 11, 2026, 6:14 PM EDT
Completed No phase listed Observational Results available

Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

NCT00388674
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
entecavir, Other anti-HBV medication
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
12,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
20
States / cities
Coronado, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 11, 2026, 6:14 PM EDT
Not listed Phase 2 Interventional

A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.

NCT00044135
View directory record Official record
Conditions
Hepatitis B
Interventions
clevudine (drug)
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 6:14 PM EDT
Active, not recruiting No phase listed Observational

Liver Cirrhosis Network Cohort Study

NCT05740358
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders

NCT04456504
View directory record Official record
Conditions
Healthcare Worker, Hepatitis B Vaccine, Nonresponder
Interventions
Recombinant hepatitis B vaccine with CpG adjuvant
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 11, 2026, 6:14 PM EDT
Completed No phase listed Observational

Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)

NCT05621304
View directory record Official record
Conditions
Chronic Hepatitis B Virus (Hbv)
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 4 Interventional Results available

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

NCT01327547
View directory record Official record
Conditions
HIV Coinfection
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
24
States / cities
Bakersfield, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients

NCT04199715
View directory record Official record
Conditions
Hepatitis B
Interventions
Heplisav-B
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

NCT04142762
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 11, 2026, 6:14 PM EDT
Completed Phase 4 Interventional Results available

Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines

NCT03530124
View directory record Official record
Conditions
Apnea, Apnea Neonatal, Prematurity
Interventions
PCV13, DTaP, HBV, IPV, Hib
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Weeks and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 11, 2026, 6:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants

NCT02366286
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 11, 2026, 6:14 PM EDT